(Q41119643)

27 September 2017

title

FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes (English)

1 reference

27 September 2017

0 references

Ono M

1

1 reference

27 September 2017

Wada Y

2

1 reference

27 September 2017

Wu Y

3

1 reference

27 September 2017

Nemori R

4

1 reference

27 September 2017

Jinbo Y

5

1 reference

27 September 2017

Wang H

6

1 reference

27 September 2017

Lo KM

7

1 reference

27 September 2017

Yamaguchi N

8

1 reference

27 September 2017

Brunkhorst B

9

1 reference

27 September 2017

Otomo H

10

1 reference

27 September 2017

Wesolowski J

11

1 reference

27 September 2017

Way JC

12

1 reference

27 September 2017

Itoh I

13

1 reference

27 September 2017

Gillies S

14

1 reference

27 September 2017

Chen LB

15

1 reference

27 September 2017

language of work or name

1 reference

1 April 1997

1 reference

27 September 2017

1 reference

27 September 2017

volume

15

1 reference

27 September 2017

issue

4

1 reference

27 September 2017

page(s)

343-348

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt0497-343

27 September 2017

exact match

0 references

cites work

Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

Identification of a major co-receptor for primary isolates of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

Viral dynamics in human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

A soluble CD4 protein selectively inhibits HIV replication and syncytium formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Neutralizing monoclonal antibodies to the AIDS virus

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Curdlan sulfate and HIV-1: II. In vitro long-term treatment of HIV-1 infection with curdlan sulfate

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Inhibition of HIV replication by derivatives of naphthalenedisulfonic acids

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Multifactorial nature of human immunodeficiency virus disease: implications for therapy

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Suppression of HIV infection in AZT-treated SCID-hu mice

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Human immunodeficiency virus infection of human-PBL-SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FNBT0497-343

7 January 2021

Identifiers

DOI

10.1038/NBT0497-343

1 reference

27 September 2017

1 reference